Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-25-002848
Filing Date
2025-01-29
Accepted
2025-01-28 17:33:00
Documents
23
Period of Report
2025-01-28

Document Format Files

Seq Description Document Type Size
1 DEF 14A arwr-20250128.htm   iXBRL DEF 14A 1038481
3 arwr-20250128_g1.jpg GRAPHIC 39289
4 arwr-20250128_g10.jpg GRAPHIC 329906
5 arwr-20250128_g2.jpg GRAPHIC 68095
6 arwr-20250128_g3.jpg GRAPHIC 54665
7 arwr-20250128_g4.jpg GRAPHIC 50524
8 arwr-20250128_g5.jpg GRAPHIC 20095
9 arwr-20250128_g6.jpg GRAPHIC 91235
10 arwr-20250128_g7.jpg GRAPHIC 150862
11 arwr-20250128_g8.jpg GRAPHIC 117340
12 arwr-20250128_g9.jpg GRAPHIC 441108
  Complete submission text file 0001628280-25-002848.txt   4941079

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT arwr-20250128.xsd EX-101.SCH 942
25 EXTRACTED XBRL INSTANCE DOCUMENT arwr-20250128_htm.xml XML 139610
Mailing Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105
Business Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105 626-696-4702
ARROWHEAD PHARMACEUTICALS, INC. (Filer) CIK: 0000879407 (see all company filings)

EIN.: 460408024 | State of Incorp.: DE | Fiscal Year End: 0930
Type: DEF 14A | Act: 34 | File No.: 001-38042 | Film No.: 25565929
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)